Market News

AxoGen, Inc. (AXGN) EPS Estimated At $-0.09; Forest Hill Capital Cut South St (SSB) Position By $2.33 Million

Forest Hill Capital Llc decreased South St Corp (SSB) stake by 29.27% reported in 2017Q3 SEC filing. Forest Hill Capital Llc sold 25,915 shares as South St Corp (SSB)’s stock declined 7.90%. The Forest Hill Capital Llc holds 62,628 shares with $5.64M value, down from 88,543 last quarter. South St Corp now has $3.13B valuation. The stock increased 1.72% or $1.45 during the last trading session, reaching $85.65. About 147,706 shares traded. South State Corporation (NASDAQ:SSB) has risen 19.60% since February 11, 2017 and is uptrending. It has outperformed by 2.90% the S&P500.

Analysts expect AxoGen, Inc. (NASDAQ:AXGN) to report $-0.09 EPS on February, 28.They anticipate $0.01 EPS change or 10.00% from last quarter’s $-0.1 EPS. After having $-0.06 EPS previously, AxoGen, Inc.’s analysts see 50.00% EPS growth. The stock increased 2.05% or $0.5 during the last trading session, reaching $24.9. About 414,682 shares traded or 28.18% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since February 11, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $848.94 million. The company's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Lake Street on Thursday, November 3. Roth Capital maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Monday, September 11. Roth Capital has “Buy” rating and $21.0 target. The stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Buy” rating by Cantor Fitzgerald on Monday, August 21. Wedbush maintained the shares of AXGN in report on Friday, August 28 with “Outperform” rating. As per Monday, January 8, the company rating was maintained by Cantor Fitzgerald. The stock has “Buy” rating by Lake Street on Tuesday, November 22. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Outperform” rating given on Monday, November 7 by Wedbush. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Outperform” rating given on Thursday, November 2 by Leerink Swann. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Tuesday, November 21 by Wedbush. On Tuesday, August 11 the stock rating was upgraded by Zacks to “Hold”.

Leave a Reply

Your email address will not be published. Required fields are marked *